Streptomycin

Summary

Streptomycin (CHEMBL372795) is an approved small-molecule antimicrobial agent (ATC J01GA01); indicated across 5 conditions including bacterial infectious disease and plague.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01GA01 (+2 more)
• Indications: 5 conditions
• Clinical trials: 6
• Chemistry: 581.6 Da · C21H39N7O12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL372795
Name	Streptomycin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	176517432
ChEBI	CHEBI:17076
ATC	J01GA01, A07AA04, A07AA54
Molecular formula	C21H39N7O12
Molecular weight	581.6
InChIKey	UCSJYZPVAKXKNQ-HZYVHMACSA-N

SMILES: C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)NC(=N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O

IUPAC name: 1-[(1R,2R,3S,4R,5R,6S)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine

ChEBI definition: A amino cyclitol glycoside that consists of streptidine having a disaccharyl moiety attached at the 4-position. The parent of the streptomycin class

Pharmacological roles (ChEBI): antimicrobial agent, antimicrobial drug, antibacterial drug, protein synthesis inhibitor, antifungal agrochemical.

Other ChEBI roles (chemical / environmental): bacterial metabolite.

Also known as: Chemform, Estreptomicina, Gerox, NSC-14083, Streptomycin, Streptomycine, Strepcen, streptomycin, Stretomycin, Streptomisin, SID29215251, Streptomycin B

Parent form; salt/anhydrous children: CHEMBL3184791

Patent coverage: 272,611 distinct patent families (784,060 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Aldehyde dehydrogenase 1A1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
plague	3	MONDO:0019095	EFO:0009425
Mycobacterium avium complex disease	2	MONDO:0005866	EFO:0007386
Buruli ulcer disease	2	MONDO:0000327	MONDO:0000327
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
Not specified	2
PHASE4	1
PHASE2/PHASE3	1
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02331823	PHASE4	UNKNOWN	Research on New Regimens for Retreatment Pulmonary Tuberculosis
NCT00128466	PHASE2/PHASE3	COMPLETED	Treatment and Diagnosis of Plague
NCT04110340	PHASE3	COMPLETED	Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
NCT00004689	PHASE2	COMPLETED	Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
NCT00004444	Not specified	COMPLETED	Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis
NCT02604849	Not specified	COMPLETED	Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).